{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:36:18Z","timestamp":1760060178315,"version":"build-2065373602"},"reference-count":47,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Myelodysplastic syndromes are clonal hematopoietic disorders characterized by ineffective hematopoiesis and risk of progression to acute myeloid leukemia. Accurate prognostic stratification is essential to guide treatment, with several scoring systems in clinical use: IPSS, IPSS-R, and WPSS. Objective: We aimed to evaluate the prognostic accuracy of IPSS, IPSS-R, and WPSS in a real-world Romanian MDS cohort by comparing risk classifications with observed overall survival and progression-free survival. Methods: We conducted a retrospective analysis of 117 patients diagnosed with MDS treated in our clinic between 2018 and 2022. All patients had confirmed diagnoses based on bone marrow biopsy and cytogenetic testing. Data were used to assign risk categories based on IPSS, IPSS-R, and WPSS. Survival outcomes were analyzed using Kaplan\u2013Meier curves and log-rank tests. Results: The median age of the cohort was 70 years; gender distribution was balanced. Transfusion dependence was present in 73.5%, and 49.6% had cytogenetic abnormalities. Overall, low-risk classification was assigned in 58.1% (IPSS), 38.5% (IPSS-R), and 38.5% (WPSS) of patients. Median OS was 20 months, and median PFS was 35 months. Although no statistically significant overall survival differences were observed across scoring systems, IPSS-R demonstrated a trend toward stronger prognostic discrimination in multivariable analysis. Reclassification of patients initially categorized as IPSS intermediate-1 revealed a significant survival impact: patients reclassified as lower-risk by IPSS-R and WPSS had a median OS of 67.5 months versus 15 months for those reclassified as higher-risk (IPSS-R: HR = 0.24; p = 0.0017; WPSS: HR = 0.26; p = 0.0031). Similarly, leukemic transformation occurred in 13.6% of reclassified lower-risk patients vs. 52.2% in higher-risk patients (IPSS-R: HR = 0.13; p = 0.0021; WPSS: HR = 0.12; p = 0.002), with a median PFS of 21 months in the higher-risk group. In multivariable Cox regression analysis, IPSS-R stratification remained a strong independent predictor for both OS (HR = 3.22; p = 0.000003) and PFS (HR = 4.77; p &lt; 0.00001), while azacitidine treatment was associated with significantly improved survival (OS: HR = 0.43; p = 0.00002) and reduced risk of progression (PFS: HR = 0.36; p = 0.013).<\/jats:p>","DOI":"10.3390\/jcm14165757","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T15:44:21Z","timestamp":1755186261000},"page":"5757","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative Analysis of IPSS, IPSS-R, and WPSS for Predicting Survival and Leukemic Transformation in Myelodysplastic Neoplasms: A Real-World Single-Center Experience"],"prefix":"10.3390","volume":"14","author":[{"given":"Mihai-Emilian","family":"Lapadat","sequence":"first","affiliation":[{"name":"Department of Hematology, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"Clinic of Hematology, Coltea Clinical Hospital, 030171 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oana","family":"Stanca","sequence":"additional","affiliation":[{"name":"Department of Hematology, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"Clinic of Hematology, Coltea Clinical Hospital, 030171 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicoleta Mariana","family":"Berbec","sequence":"additional","affiliation":[{"name":"Department of Hematology, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"Clinic of Hematology, Coltea Clinical Hospital, 030171 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvana","family":"Angelescu","sequence":"additional","affiliation":[{"name":"Department of Hematology, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"Clinic of Hematology, Coltea Clinical Hospital, 030171 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina Nicoleta","family":"Triantafyllidis","sequence":"additional","affiliation":[{"name":"Department of Hematology, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"Clinic of Hematology, Coltea Clinical Hospital, 030171 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anca Mariana","family":"Ciobanu","sequence":"additional","affiliation":[{"name":"Clinic of Hematology, Coltea Clinical Hospital, 030171 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6227-0356","authenticated-orcid":false,"given":"Cristina","family":"Negotei","sequence":"additional","affiliation":[{"name":"Department of Hematology, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"Clinic of Hematology, Coltea Clinical Hospital, 030171 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9009-5240","authenticated-orcid":false,"given":"Cristian Tudor","family":"Barta","sequence":"additional","affiliation":[{"name":"Department of Hematology, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"Clinic of Hematology, Coltea Clinical Hospital, 030171 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8349-0169","authenticated-orcid":false,"given":"Georgian","family":"Halcu","sequence":"additional","affiliation":[{"name":"Department of Hematology, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"Clinic of Hematology, Coltea Clinical Hospital, 030171 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6213-0142","authenticated-orcid":false,"given":"Carmen","family":"Saguna","sequence":"additional","affiliation":[{"name":"Department of Hematology, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"Clinic of Hematology, Coltea Clinical Hospital, 030171 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constanta Elena","family":"Popovici","sequence":"additional","affiliation":[{"name":"Department of Hematology, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"Clinic of Hematology, Coltea Clinical Hospital, 030171 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana-Maria","family":"Bordea","sequence":"additional","affiliation":[{"name":"Clinic of Hematology, Coltea Clinical Hospital, 030171 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madalina Marilena","family":"Oprea","sequence":"additional","affiliation":[{"name":"Clinic of Hematology, Coltea Clinical Hospital, 030171 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrei","family":"Colita","sequence":"additional","affiliation":[{"name":"Department of Hematology, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"Clinic of Hematology, Coltea Clinical Hospital, 030171 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/nrc.2016.112","article-title":"The genetics of myelodysplastic syndrome: From clonal haematopoiesis to secondary leukaemia","volume":"17","author":"Sperling","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"El Hussein, S., and Loghavi, S. (2022). The impact of clonal hierarchy and heterogeneity on phenotypic manifestations of myelodysplastic neoplasms. Cancers, 14.","DOI":"10.3390\/cancers14225690"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1056\/NEJMoa1106968","article-title":"Clonal architecture of secondary acute myeloid leukemia","volume":"366","author":"Walter","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1053\/j.seminhematol.2024.09.004","article-title":"Therapy-related myelodysplastic syndromes and acute myeloid leukemia","volume":"61","author":"Venugopal","year":"2024","journal-title":"Semin. Hematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1200\/JCO.2006.08.5696","article-title":"Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes","volume":"25","author":"Malcovati","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"EVIDoa2200008","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular international prognostic scoring system for myelodysplastic syndromes","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evid."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1002\/ajh.25234","article-title":"Prognosis of patients with intermediate risk IPSS-R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS-R","volume":"93","author":"Benton","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1182\/blood-2022-163634","article-title":"Real-world validation of molecular international prognostic scoring system (IPSS-M) for myelodysplastic syndromes","volume":"140","author":"Sauta","year":"2022","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"9813","DOI":"10.1182\/blood-2022-170980","article-title":"Assessment of the molecular international prognostic scoring system (IPSS-M) risk stratification model in therapy-related myelodysplastic syndromes","volume":"140","author":"Aguirre","year":"2022","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"6966","DOI":"10.1182\/blood-2022-168705","article-title":"IPSS-M applicability and clinical impact in decision-making process in real-life clinical practice","volume":"140","author":"Palomo","year":"2022","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/s41375-023-01831-1","article-title":"Risk prediction in MDS: Independent validation of the IPSS-M\u2014Ready for routine?","volume":"37","author":"Baer","year":"2023","journal-title":"Leukemia"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s40164-022-00328-4","article-title":"IPSS-M has greater survival predictive accuracy compared with IPSS-R in persons \u2265 60 years with myelodysplastic syndromes","volume":"11","author":"Wu","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"240820","DOI":"10.7754\/Clin.Lab.2024.240820","article-title":"Prognostic impact of transfusion dependency in patients with lower-risk myelodysplastic syndrome","volume":"71","author":"Lee","year":"2025","journal-title":"Clin. Lab."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/ejh.13619","article-title":"Association between red blood cell transfusion dependence and burden in patients with myelodysplastic syndromes: A systematic literature review and meta-analysis","volume":"107","author":"Rodrigues","year":"2021","journal-title":"Eur. J. Haematol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Wiseman, T., Spooner, M., Khanna, S., Hung, K., Toop, C., Kutyna, M.M., Yu, J., Brown, A.L., Scott, H.S., and Hahn, C.N. (2025). RBC transfusion dependency refines the molecular international prognostic scoring system for myelodysplastic syndrome. Blood Adv.","DOI":"10.1182\/bloodadvances.2025016086"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"66","DOI":"10.6004\/jnccn.2025.0013","article-title":"Myelodysplastic syndromes, Version 2.2025 featured updates to the NCCN guidelines","volume":"23","author":"Greenberg","year":"2025","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.annonc.2020.11.002","article-title":"Myelodysplastic syndromes: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Fenaux","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/bjh.17640","article-title":"2021 BSH guidelines for the management of adult myelodysplastic syndromes: A practical approach to a challenging disease","volume":"194","author":"Ferrara","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1002\/ajh.26984","article-title":"Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management","volume":"98","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1038\/s41375-023-02031-7","article-title":"Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts","volume":"37","author":"Platzbecker","year":"2023","journal-title":"Leukemia"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(23)01724-5","article-title":"Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): A multinational, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"403","author":"Platzbecker","year":"2023","journal-title":"Lancet"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Symeonidis, A., Diamantopoulos, P., Galanopoulos, A., Kourakli, A., Sazakli, E., Hatzimichael, E., Pagoni, M., Zikos, P., Vassilakopoulos, T.P., and Gavrilaki, E. (2025). Lenalidomide efficacy in patients with MDS and del-5q: Real-world data from the Hellenic (Greek) National Myelodysplastic & Hypoplastic Syndromes Registry (EAKMYS). Cancers, 17.","DOI":"10.3390\/cancers17091388"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Kasprzak, A., Kaivers, J., Nachtkamp, K., Haas, R., Kobbe, G., Gattermann, N., and Germing, U. (2021). Guidelines for myelodysplastic syndromes: Converting evidence into action?. Int. J. Environ. Res. Public Health, 18.","DOI":"10.3390\/ijerph18147629"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"6486","DOI":"10.1182\/blood-2023-188855","article-title":"Azacitidine treatment in MDS: A systematic literature review and meta-analysis comparing the efficacy of real world data with randomized controlled trials","volume":"142","author":"Rupp","year":"2023","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.21792","article-title":"Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S2352-3026(23)00338-1","article-title":"Oral decitabine\u2013cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): A registrational, randomised, crossover, pharmacokinetics, phase 3 study","volume":"11","author":"McCloskey","year":"2024","journal-title":"Lancet Haematol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1158\/2643-3230.BCD-22-0205","article-title":"A Phase Ib\/II Study of Ivosidenib with Venetoclax \u00b1 Azacitidine in IDH1-Mutated Myeloid Malignancies","volume":"4","author":"Lachowiez","year":"2023","journal-title":"Blood Cancer Discov."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/ajh.26771","article-title":"A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes","volume":"98","author":"Zeidan","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1038\/s41409-024-02365-5","article-title":"Superior outcome of upfront allogeneic hematopoietic cell transplantation versus hypomethylating agent induction in myelodysplastic syndrome","volume":"59","author":"Schroeder","year":"2024","journal-title":"Bone Marrow Transplant."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jtct.2022.11.014","article-title":"Hematopoietic cell transplantation in the management of myelodysplastic syndrome: An evidence-based review from the American Society for Transplantation and Cellular Therapy Committee on Practice Guidelines","volume":"29","author":"DeFilipp","year":"2023","journal-title":"Transplant. Cell. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1056\/NEJMra1904794","article-title":"Myelodysplastic Syndromes","volume":"383","author":"Cazzola","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_35","first-page":"783","article-title":"Myelodysplastic syndromes: Diagnosis, prognosis, and treatment","volume":"110","author":"Germing","year":"2013","journal-title":"Dtsch. Arztebl. Int."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1001\/jama.2022.14578","article-title":"Diagnosis and treatment of myelodysplastic syndromes: A review","volume":"328","author":"Sekeres","year":"2022","journal-title":"JAMA"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/10428194.2018.1464155","article-title":"Transfusion-free interval is associated with improved survival in patients with higher-risk myelodysplastic syndromes engaged in routine care","volume":"60","author":"Bell","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"216","DOI":"10.5045\/br.2014.49.4.216","article-title":"Pathogenesis of myelodysplastic syndromes: An overview of molecular and non-molecular aspects of the disease","volume":"49","author":"Visconte","year":"2014","journal-title":"Blood Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"956","DOI":"10.3324\/haematol.2013.085217","article-title":"Clinical and genetic predictors of prognosis in myelodysplastic syndromes","volume":"99","author":"Bejar","year":"2014","journal-title":"Haematologica"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1200\/JCO.2010.31.3353","article-title":"Association of comorbidities with overall survival in myelodysplastic syndrome: Development of a prognostic model","volume":"29","author":"Naqvi","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1182\/bloodadvances.2020003381","article-title":"Comorbidities and malignancies negatively affect survival in myelodysplastic syndromes: A population-based study","volume":"5","author":"Rozema","year":"2021","journal-title":"Blood Adv."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","article-title":"Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the Cancer and Leukemia Group B","volume":"20","author":"Silverman","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_43","first-page":"2157","article-title":"Patterns of lower risk myelodysplastic syndrome progression: Factors predicting progression to high-risk myelodysplastic syndrome and acute myeloid leukemia","volume":"109","author":"Jain","year":"2024","journal-title":"Haematologica"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/bjh.15243","article-title":"Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population-based setting: A report from the Swedish MDS register","volume":"181","author":"Folkvaljon","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"119","DOI":"10.4274\/tjh.2014.0455","article-title":"Comparison of myelodysplastic syndrome prognostic scoring systems","volume":"33","author":"Bektas","year":"2016","journal-title":"Turk. J. Hematol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1182\/blood.V120.21.3841.3841","article-title":"Comparison of IPSS and IPSS-R scoring in a population-based myelodysplastic syndromes (MDS) study","volume":"120","author":"Warlick","year":"2012","journal-title":"Blood"},{"key":"ref_47","first-page":"556024","article-title":"The prediction of survival by standard prognostic scoring systems and comorbidity indexes in myelodysplastic syndrome: A hospital-based study","volume":"19","author":"Selda","year":"2021","journal-title":"Cancer Ther. Oncol. Int. J."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/16\/5757\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:27:32Z","timestamp":1760034452000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/16\/5757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,14]]},"references-count":47,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["jcm14165757"],"URL":"https:\/\/doi.org\/10.3390\/jcm14165757","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,14]]}}}